Европейский союз - исландский - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dímetýl fúmarat - heila-og mænusigg, köstum tilkynnt - Ónæmisbælandi lyf - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Европейский союз - исландский - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - risperidone - geðklofa - psycholeptics - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Европейский союз - исландский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - lipoteichoic sýru frá biofilm niður hluti af læknafélag uberis, álag 5616 - Ónæmisfræðilegar rannsóknir á nautgripum - nautgripir - fyrir virk bólusetningar heilbrigt kýr og kvígur til að draga úr tíðni klínískum spenalyf sýkingar af völdum læknafélag uberis, til að draga úr líkamsvöxt blóðkorna í læknafélag uberis jákvæð ársfjórðungi mjólk sýni og til að draga úr mjólk framleiðslu tap af völdum læknafélag uberis spenalyf sýkingum.

Европейский союз - исландский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svín - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios hipra s.a.* - ceftiofurum hýdróklóríð - stungulyf, dreifa - 50 mg/ml

Европейский союз - исландский - EMA (European Medicines Agency)

laboratorios hipra, s.a. - bóluefni gegn hníslalyfjum í kjúklingum - lifandi sníkjudýra bóluefni, Ónæmislyf fyrir aves - kjúklingur - fyrir virk bólusetningar kjúklinga frá 1 dag aldri til að draga úr klínískum merki (niðurgangur), þarma sár og eaablöðrur framleiðsla tengslum við hníslasótt af völdum eimeria acervulina, eimeria brunetti, eimeria maxima, eimeria necatrix og eimeria tenella.

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios hipra s.a.* - escherichia coli f4ab fimbrial adhesin; escherichia coli f4ac fimbrial adhesin; escherichia coli f5 fimbrial adhesin; escherichia coli f6 fimbrial adhesin; escherichia coli lt enterotoxoid; clostridium perfringens type-c beta toxoid; clostridium novyi toxoid - stungulyf, dreifa

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - anidulafunginum inn - stofn fyrir innrennslisþykkni, lausn - 100 mg

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios syva s.a.u. - medetomidinum hýdróklóríð - stungulyf, lausn - 1 mg/ml

Исландия - исландский - LYFJASTOFNUN (Icelandic Medicines Agency)

laboratorios normon s.a. - cyanocobalaminum inn - stungulyf, lausn - 1000 míkróg